Sodium chloride


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Chronic salt-losing conditions Extended release 2.4-4.8 g/day, up to 12 g/day. Prevention of muscle cramps during routine haemodialysis Extended release 6-10 g/dialysis session. Mouth/Throat Oral hygiene As mouthwash: Use as directed. IV Replacement of fluid and electrolytes As 0.9, 3 or 5% soln: Dosage depends on age, wt, clinical condition and laboratory determinations of the patient. Hypernatraemia As 0.9% soln: Dosage depends on age, wt, clinical condition and laboratory determinations of the patient. Nasal Nasal congestion As 0.9% soln/spray: Use as directed. Irrigation Irrigation of the bladder, eye, general skin and wound cleansing As 0.9% soln: Use as directed.
Dosage Details
Intravenous
Hypernatraemia
Adult: Dosage, rate, and duration of administration are to be individualised and depends on age, weight, clinical condition,  and laboratory response to treatment.

Intravenous
Replacement of fluid and electrolytes
Adult: Dosage, rate, and duration of administration are to be individualised and depends on age, weight, fluid/electrolyte condition, and on the patient’s clinical and laboratory response to treatment.

Irrigation
Irrigation of the bladder, eye, general skin and wound cleansing
Adult: As 0.9% solution: Use as required.

Nasal
Nasal congestion
Adult: As 0.9% solution: Use as required.
Child: 0.9% used as nasal drops.

Oral
Prophylaxis of muscle cramps during routine haemodialysis
Adult: As modified-release preparation: 6-10 g every dialysis session.

Oral
Chronic salt-losing conditions
Adult: As modified-release preparation: 2.4-4.8 g (40-80 mmol sodium) daily accompanied by suitable fluid intake. Up to 12 g daily may be necessary in severe cases.

Oral
Oral hygiene
Adult: As mouthwash: Rinse or gargle as required.
Renal Impairment
Oral:
Chronic salt-losing conditions: Dosage adjustment may be necessary.
Contraindications
Conditions whereby admin of sodium chloride would be detrimental. Not to be used to induce emesis. Sustained release tablets: GI disorders associated with strictures or diverticula.
Special Precautions
Hypertension, heart failure, peripheral or pulmonary oedema, impaired renal function, liver cirrhosis, preeclampsia. Maintain adequate water intake. Pregnancy. Inj of 3 or 5% sodium chloride solution should be given via a large vein at a rate not exceeding 100 ml/hr. Monitor fluid balance, serum electrolytes and acid base balance espcially during prolonged treatment. Caution when used in patients who are receiving corticosteroids or corticotropin.
Adverse Reactions
Hypernatraemia; thirst, reduced salivation and lachrymation, fever, tachycardia, hypertension, headache, dizziness, restlessness, irritability and weakness.
Potentially Fatal: Intra-amniotic inj of hypertonic solutions: Disseminated intravascular coagulation, renal necrosis, cervical and uterine lesions, pulmonary embolism, pneumonia and death.
Inhalation/Respiratory/Irrigation/IV/Nasal/Ophth/Parenteral/PO: C
Drug Interactions
May affect serum concentrations of lithium.
Action
Description: Sodium chloride is the major extracellular cation. It is important in electrolyte and fluid balance, osmotic pressure control and water distribution as it restores sodium ions. It is used as a source of electrolytes and water for hydration, treatment of metabolic acidosis, priming solution in haemodialysis and treatment of hyperosmolar diabetes. It is also used as diluents for infusion of compatible drug additives.
Pharmacokinetics:
Absorption: Well-absorbed from the GI tract.
Excretion: Mainly in the urine, with small amounts excreted in the sweat, faeces, tears and saliva.
Disclaimer: This information is independently developed by MIMS based on Sodium chloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • NS Albert David
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in